Navigation Links
Stemedica Requests Pre-IND Meeting With FDA
Date:8/21/2009

SAN DIEGO, Aug. 21 /PRNewswire/ -- Stemedica Cell Technologies, Inc. USA, a leader in adult stem cell research and manufacturing, has requested a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration ("FDA") to discuss a proposed IND to use Stemedica's proprietary line of allogeneic mesenchymal bone marrow cells (adult human) as a treatment for ischemic stroke.

Stroke is a leading cause of adult impairment, with 20% of stroke survivors requiring institutional care after 3 months and up to 30% severely and permanently disabled. The only approved treatments of acute ischemic stroke involves restoring blood flow to the affected region by using thrombolytics or mechanical devices that physically remove clots. However, the use of thrombolytics (tPA) is limited due to the therapeutic window of < 3-6 hours post onset of stroke symptoms such that only a small fraction of stroke patients receive this therapy.

"Following a stroke, there is little therapy to offer patients to promote recovery other than physical, occupational, and speech therapy," said Nikolai Tankovich, MD, PhD, President & Chief Medical Officer. "Treatment with allogeneic mesenchymal bone marrow cells may offer new hope to patients with chronic neurological or age-related, neurodegenerative diseases."

Allogeneic mesenchymal bone marrow cells are obtained from donors by extracting bone marrow and are expanded at Stemedica's cGMP compliant facility, which is licensed by the California Department of Public Health, Food and Drug Branch. "Stemedica's facility will manufacture clinical grade stem cells as it prepares for FDA approval of an IND to begin clinical trials," said Maynard Howe, PhD, Vice Chairman and CEO of Stemedica.

About Stemedica C
'/>"/>

SOURCE Stemedica Cell Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
2. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
3. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
6. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
7. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
8. Biopure Reports on Meeting with the FDA
9. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
10. Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting
11. Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining ... delivery systems especially for type 1 diabetes ...
(Date:1/15/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") ... its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for ... Solta Medical, Inc. (NASDAQ: SLTM ) ("Solta") ... the seller in cash, without interest (less any required ...
(Date:1/15/2014)... , Jan. 15, 2014 /PRNewswire/ ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ... OBJECTIVES A drug delivery ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... Trial to Examine Safety and Efficacy of DARA ... Pharmacopeia,(Nasdaq: PCOP ), an innovator in ... today announced the initiation of a Phase 2b,clinical ... candidate.,This randomized, double-blind, placebo and active-controlled,parallel-group study is ...
... 29 A study reported in,the journal ... the,Ciliary Neurotrophic Factor gene (CNTF) may affect ... Vanda Pharmaceuticals,Inc., included patients with acute symptoms ... (iloperidone), a novel atypical,antipsychotic agent currently under ...
Cached Medicine Technology:Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA) 2Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA) 3Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA) 4Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm (iloperidone) 2Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm (iloperidone) 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... first time, researchers at the University of California, San Diego ... processes that power the celebrated health benefits of omega-3 fatty ... be possible to manipulate these processes to short-circuit inflammation before ... it becomes detrimental. The work is published in the ...
... in June,s Journal of Thoracic Oncology says molecular ... be an additional predictive technique for lung cancer screening. ... percent of the positive CT screening results were false positive, ... patients. This research focused on a way to determine if ...
... By Alan Mozes HealthDay Reporter , TUESDAY, May ... a silver bullet when it comes to symptom relief for ... analysis of six prior studies found that the sprays confer ... taken for three weeks at relatively high doses. The ...
... resident Maureen T. Kavanah, MD, an Associate Professor ... (BUSM) and a surgical oncologist at Boston Medical ... Surgical Adjuvant Breast and Bowel Project (NSABP) Distinguished ... and meritorious service to the NSABP in support ...
... for Idiopathic Toe Walking Based on Child,s Age and Severity ... walking pattern, or gait, by age 2. And while some ... the foot or toes, never touching the heel to the ... a neurological disorder. A review article, "Idiopathic Toe Walking," ...
... journal of the American Gastroenterological Association (AGA) Institute, are ... anticipated special 13th issue. Published each May, the 13th ... broad interest; this year,s topic is viral hepatitis. ... PhD, this issue was developed by Gastroenterology,s experts in ...
Cached Medicine News:Health News:Why omega-3 oils help at the cellular level 2Health News:Steroid Nasal Sprays Show Small Benefit for Sinusitis: Study 2Health News:Steroid Nasal Sprays Show Small Benefit for Sinusitis: Study 3Health News:Boston researcher, surgical oncologist receives national award 2Health News:Clinical news alert: Journal of the American Academy of Orthopaedic Surgeons May highlights 2Health News:Gastroenterology special issue focuses on new directions of viral hepatitis care and research 2Health News:Gastroenterology special issue focuses on new directions of viral hepatitis care and research 3
... The new Finnpipette Focus ... specifically to combine ergonomics with ... interchangeable handle plate offers a ... sizes. The new shorter tip ...
500L...
... The new Finnpipette Focus from ... to combine ergonomics with uncompromising ... handle plate offers a custom ... The new shorter tip cones ...
Inquire...
Medicine Products: